Department of Neurology, School of Medicine, Kyungpook National University, Daegu, Korea.
Division of Rheumatology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
J Korean Med Sci. 2020 Jun 1;35(21):e201. doi: 10.3346/jkms.2020.35.e201.
The neurologic manifestations concerning coronavirus disease 2019 (COVID-19) are highly penetrated. Anosmia and ageusia are one of the common acute neurologic symptoms, which develop in the early stage of COVID-19. However, it is not reported that how immunosuppressive agents affect these symptoms. We report olfactory and gustatory dysfunctions in a patient with ankylosing spondylitis (AS) treated with etanercept during COVID-19. A 53-year-old female showing AS controlled with tumor necrosis factor-α inhibitor, etanercept, had been diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, presenting cough and rhinorrhea. One month after diagnosis, she complained about hyposmia and hypogeusia two days before the seronegative conversion of SARS-CoV-2, which were confirmed by a neurological examination. We speculate that the etanercept may have delayed the development of olfactory and gustatory dysfunction in the patient.
新型冠状病毒病 2019（COVID-19）的神经表现高度渗透。嗅觉和味觉丧失是 COVID-19 的常见急性神经症状之一，出现在 COVID-19 的早期阶段。然而，目前尚不清楚免疫抑制剂如何影响这些症状。我们报告了一名接受依那西普治疗的强直性脊柱炎（AS）患者在 COVID-19 期间出现嗅觉和味觉功能障碍。一名 53 岁女性，患有 AS，经肿瘤坏死因子-α抑制剂依那西普控制，被诊断为严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染，表现为咳嗽和流涕。在诊断一个月后，她在 SARS-CoV-2 血清阴性转化前两天抱怨嗅觉和味觉减退，经神经科检查证实。我们推测依那西普可能延迟了患者嗅觉和味觉功能障碍的发展。
Zotero 插件